CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Akouos Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Akouos Inc
645 SUMMER STREET, SUITE 200
Phone: (857) 410-1818p:857 410-1818 BOSTON, MA  02210  United States Fax: (302) 655-5049f:302 655-5049
This company was Merged or Acquired on 12/1/2022.
This company ceased filing statements with the SEC on 12/12/2022.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Akouos Inc. precision genetic medicine company focused on developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals. The Company is focused on developing precision therapies for forms of sensorineural hearing loss. The Company's genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus commonly used in gene therapy, known as adeno-associated virus (AAV), and a novel delivery approach. The Company is focused on executing its initiatives, which include the advancement of its lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene; expansion of its pipeline to include programs focused on other monogenic conditions as well as inner ear conditions of complex etiology, such as AK-antiVEGF for vestibular schwannoma; and development of internal manufacturing capabilities, and a commercial infrastructure.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202212/31/2021YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Arthur O.Tzianabos 59 8/5/2020 7/1/2018
President, Chief Executive Officer, Co-Founder, Director Emmanuel J.Simons 39 3/1/2016
Co-Founder, Chief Medical Officer Michael J.Mckenna 65 6/1/2018 3/1/2016
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Akouos Securities Corporation
AKUS

General Information
Number of Employees: 103 (As of 2/28/2022)
Outstanding Shares: 36,946,211 (As of 10/31/2022)
Shareholders: 34
Stock Exchange: NASD
Federal Tax Id: 811716654
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 11, 2024